Endo International Past Earnings Performance

Past criteria checks 0/6

Endo International's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been declining at an average rate of 6.8% per year.

Key information

-41.7%

Earnings growth rate

-40.7%

EPS growth rate

Pharmaceuticals Industry Growth	14.1%
Revenue growth rate	-6.8%
Return on equity	n/a
Net Margin	-121.7%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Endo International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0Y5F Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	2,012	-2,448	568	115
30 Sep 23	2,070	-252	598	118
30 Jun 23	2,160	-942	652	118
31 Mar 23	2,182	-2,847	697	119
31 Dec 22	2,319	-2,910	758	121
30 Sep 22	2,552	-3,221	832	129
30 Jun 22	2,783	-2,552	881	123
31 Mar 22	2,928	-681	870	122
31 Dec 21	2,993	-569	841	122
30 Sep 21	2,964	129	767	147
30 Jun 21	2,827	109	687	150
31 Mar 21	2,801	137	688	151
31 Dec 20	2,903	247	671	120
30 Sep 20	2,908	-102	661	125
30 Jun 20	3,002	-75	667	133
31 Mar 20	3,014	-190	648	129
31 Dec 19	2,914	-361	632	131
30 Sep 19	2,936	-418	639	122
30 Jun 19	2,952	-522	635	125
31 Mar 19	2,967	-477	630	181
31 Dec 18	2,947	-962	646	186
30 Sep 18	2,929	-968	640	209
30 Jun 18	2,971	-921	612	209
31 Mar 18	3,132	-1,565	620	168
31 Dec 17	3,469	-1,233	615	172
30 Sep 17	3,942	-4,294	666	170
30 Jun 17	4,039	-4,386	717	175
31 Mar 17	4,084	-3,300	754	185
31 Dec 16	4,010	-3,224	771	183
30 Sep 16	3,842	553	802	181
30 Jun 16	3,704	-59	760	158
31 Mar 16	3,518	-539	721	126
31 Dec 15	3,269	-300	704	102
30 Sep 15	2,858	-725	592	89
30 Jun 15	2,766	128	649	88
31 Mar 15	2,624	260	616	100
31 Dec 14	2,381	58	568	113
30 Sep 14	2,303	-643	609	116
30 Jun 14	2,310	-637	599	132
31 Mar 14	2,429	-650	722	135
31 Dec 13	2,125	189	574	97
30 Sep 13	2,621	-628	829	145
30 Jun 13	2,711	-629	848	157

Quality Earnings: 0Y5F is currently unprofitable.

Growing Profit Margin: 0Y5F is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0Y5F is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Accelerating Growth: Unable to compare 0Y5F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0Y5F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).

Return on Equity

High ROE: 0Y5F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Endo International Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.20 profit in 1Q 2021)

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Fourth Amended Reorganization Plan Filed by Endo International plc

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc, Annual General Meeting, Sep 07, 2023

Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection

Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Two Affiliate Companies Joined Endo International plc Bankruptcy

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index

Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

Endo International Receives Non-Compliance Notice from Nasdaq

Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.20 profit in 1Q 2021)

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Investor sentiment deteriorated over the past week

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Investor sentiment deteriorated over the past week

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index

Investor sentiment deteriorated over the past week

Chairman Paul Campanelli has left the company

Investor sentiment improved over the past week

Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020)

Endo International plc Provides Revenue Guidance for the Year 2021

Independent Director recently sold US$150k worth of stock

Investor sentiment deteriorated over the past week

Endo International plc Appoints Jennifer M. Chao as Director, Audit Committee and its Compliance Committee

Endo International plc(NasdaqGS:ENDP) dropped from S&P 500 - Pharmaceuticals (Industry)

Endo International plc to Report Q4, 2020 Results on Feb 25, 2021

Endo International plc (NasdaqGS:ENDP) completed the acquisition of BioSpecifics Technologies Corp. (NasdaqGM:BSTC) from Edwin H. Wegman Marital Trust, Renaissance Technologies Corp., BlackRock, Inc. (NYSE:BLK).

Morganti & Co., P.C. Announce the Settlement Approval of the Endo International plc Securities Class Action

Revenue beats expectations

Third quarter 2020 earnings released: US$0.30 loss per share

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta